Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

1. Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations

Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations To determine whether 2 doses of dexamethasone is as effective as 5 days of prednisolone/prednisone therapy in improving symptoms and quality of life of children with asthma exacerbations admitted to the emergency department (ED).We conducted a randomized, noninferiority trial including patients aged 1-14 years who presented to the ED with acute asthma to compare the efficacy of 2 doses (...) of dexamethasone (0.6 mg/kg/dose, experimental treatment) vs a 5-day course of prednisolone/prednisone (1.5 mg/kg/d, followed by 1 mg/kg/d on days 2-5, conventional treatment). Two follow-up telephone interviews were completed at 7 and 15 days. The primary outcome measures were the percentage of patients with asthma symptoms and quality of life at day 7. Secondary outcomes were unscheduled returns, admissions, adherence, and vomiting.During the study period, 710 children who met the inclusion criteria were

2018 EvidenceUpdates

2. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations?

Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? Systematic Review Snapshot TAKE-HOME MESSAGE The use of 1 to 2 doses of dexamethasone for acute pediatric asthma exacerbation does not appear to increase the frequency of unscheduled return visits compared with a 5-day course of prednisone or prednisolone. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? EBEM (...) . 2 Although treatment with broncho- dilators is typically used to reverse acute bronchoconstriction, cortico- steroids are also a mainstay of therapy aimed at reducing in- ?ammation and mucous plugging. 3 Traditionally, corticosteroids have been prescribed as a 5-day course of either oral prednisone or predniso- lone; the goal of this systematic re- view was to determine whether a Table. Pooled RR of relapse* for dexamethasone versus prednisone/prednisolone at various intervals. Rate of Relapse

2015 Annals of Emergency Medicine Systematic Review Snapshots

3. Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial (Full text)

Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial We evaluate the efficacy of a 4-day course of prednisone added to antihistamine for the management of acute urticaria in an emergency department (ED).In this double-blind randomized clinical trial, patients were eligible for inclusion if aged 18 years or older and with acute urticaria of no more than 24 hours' duration. Patients with anaphylaxis (...) or who had received antihistamines or glucocorticoids during the previous 5 days were not included. In addition to levocetirizine (5 mg orally for 5 days), patients were assigned to receive prednisone (40 mg orally for 4 days) or placebo. The primary endpoint of the study was itching relief 2 days after the ED visit, rated on a numeric scale of 0 to 10. Secondary endpoints were rash resolution, relapses, and adverse events.A total of 100 patients were included, 50 in each group. Seven patients

2017 EvidenceUpdates

4. Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away?

Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary (...) care research. www.acfp.ca May 9, 2016 Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Clinical Question: Are 1-2 doses of dexamethasone as effective as the standard five day prednisone regimen for treatment of pediatric asthma exacerbations? Bottom-line: Treatment of pediatric asthma exacerbations with short-course dexamethasone (0.6 mg/kg x 1-2 doses) is a safe and effective alternative to traditional five day courses of prednisone. For every ~20

2016 Tools for Practice

5. Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department

Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Article Text Therapeutics Systematic review and meta-analysis Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Annie L Andrews 1 , Annie N Simpson 2 Statistics from Altmetric.com Commentary on: Keeney GE , Gray MP , Morrison AK , et al . Dexamethasone for acute asthma

2014 Evidence-Based Medicine

6. Prednisone

Prednisone Top results for prednisone - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prednisone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

7. The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients With Bell?s Palsy: A Systematic Review

The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients With Bell?s Palsy: A Systematic Review "The Efficacy of Prednisone Versus Antivirals in the Complete Recovery " by Robin Tyner < > > > > > Title Author Date of Graduation Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Bell’s palsy is an idiopathic condition, caused by inflammatory injury to the facial nerve, resulting (...) viral etiology. Does the use of antivirals alone or in conjunction with steroids substantially increase the overall recovery in patients with Bell’s palsy? Methods: An exhaustive search was conducted using Medline-OVID, CINAHL-EBSCOhost, EBMR Multifile, and Web of Science using the keywords: Bell’s palsy, antiviral agents and prednisone or prednisolone. The NIH clinical trials site revealed no on-going or registered trials comparing the treatment of steroids and antivirals in patients with Bell’s

2013 Pacific University EBM Capstone Project

8. Randomized trial of dexamethasone versus prednisone for children with acute asthma exacerbations: why? (Full text)

Randomized trial of dexamethasone versus prednisone for children with acute asthma exacerbations: why? 29550227 2019 02 15 2019 02 15 1097-6833 197 2018 06 The Journal of pediatrics J. Pediatr. Randomized trial of dexamethasone versus prednisone for children with acute asthma exacerbations: why? 316-317 S0022-3476(18)30137-9 10.1016/j.jpeds.2018.01.059 Weinberger Miles M University of California San Diego Department of Pediatrics Rady Children's Hospital San Diego, California; Professor (...) Emeritus University of Iowa Iowa City, Iowa. eng Letter Comment 2018 03 15 United States J Pediatr 0375410 0022-3476 0 Anti-Asthmatic Agents 7S5I7G3JQL Dexamethasone 9PHQ9Y1OLM Prednisolone VB0R961HZT Prednisone AIM IM J Pediatr. 2017 Dec;191:190-196.e1 29173304 J Pediatr. 2018 Jun;197:317-318 29567044 Anti-Asthmatic Agents Asthma Child Dexamethasone Humans Prednisolone Prednisone 2017 12 19 2018 01 22 2018 3 20 6 0 2019 2 16 6 0 2018 3 19 6 0 ppublish 29550227 S0022-3476(18)30137-9 10.1016/j.jpeds

2019 The Journal of pediatrics Controlled trial quality: uncertain

9. Dexamethasone Compared to Prednisone for the Treatment of Children With Acute Asthma Exacerbations. (Full text)

Dexamethasone Compared to Prednisone for the Treatment of Children With Acute Asthma Exacerbations. Systemic corticosteroids are recommended in clinical practice guidelines for the treatment of acute asthma exacerbation based on evidence demonstrating reduced hospitalizations and improved outcomes after administration in the emergency department. Although prednisone and related oral preparations have been recommended previously, researchers have assessed dexamethasone as an alternative based (...) on its longer biologic half-life and improved palatability. Systematic reviews of multiple small trials and 2 larger trials have found no difference in revisits to the emergency department compared to prednisone for dexamethasone given either as an intramuscular injection or orally. Studies of oral administration have found reduced emesis for dexamethasone compared to prednisone both in the emergency department and for a second oral dose, typically given 24 to 48 hours later. Studies assessing

2018 Pediatric Emergency Care

10. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone | European Medicines Agency Search Search Menu Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Ongoing clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating (...) the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA's ( ) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate cancer patients. In this study 34.7% of patients treated with Xofigo, Zytiga and prednisone/prednisolone have died so far, compared with 28.2% of patients given placebo, Zytiga and prednisone

2018 European Medicines Agency - EPARs

11. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. (PubMed)

Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. To compare the clinical course of patients with class III, IV and V lupus nephritis (LN) treated at Hospital Universitario Cruces (CC) and at Bordeaux University Hospital (BC).The Lupus-Cruces nephritis protocol combines pulses of 125mg of methyl-prednisolone with each fortnightly (...) pulse of cyclophosphamide and prednisone ≤30mg/day with tapering over 12-14weeks until 2.5-5mg/day. The BC followed international lupus nephritis guidelines, combining high-dose prednisone and either mycophenolate mofetil or cyclophosphamide, followed by maintenance therapy with low dose prednisone and immunosuppressive drugs. The main outcomes were complete renal remission (CR) and glucocorticoid toxicity.44 patients from BC and 29 from CC were included. The mean maximum prednisone dose was 42.5

2017 Autoimmunity reviews

12. A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma. (PubMed)

A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma. Oral dexamethasone demonstrates bioavailability similar to that of oral prednisone but has a longer half-life. We evaluate whether a single dose of oral dexamethasone plus 4 days of placebo is not inferior to 5 days of oral prednisone in treatment of adults with mild to moderate asthma exacerbations to prevent relapse defined as an unscheduled return visit (...) for additional treatment for persistent or worsening asthma within 14 days.Adult emergency department patients (aged 18 to 55 years) were randomized to receive either a single dose of 12 mg of oral dexamethasone with 4 days of placebo or a 5-day course of oral prednisone 60 mg a day. Outcomes including relapse were assessed by a follow-up telephone interview at 2 weeks.One hundred seventy-three dexamethasone and 203 prednisone subjects completed the study regimen and telephone follow-up. The dexamethasone

2016 Annals of Emergency Medicine Controlled trial quality: predicted high

13. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. (Full text)

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma.In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma (...) who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival.At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7

2017 NEJM Controlled trial quality: predicted high

14. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. (PubMed)

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve (...) either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group), or 1000 mg of intravenous rituximab on days 0 and 14, and 500 mg at months 12 and 18, combined with a short-term prednisone regimen, 0·5 or 1·0 mg/kg per day tapered over 3 or 6 months (rituximab plus short-term prednisone group). Follow-up was for 3 years (study visits were scheduled weekly during the first month of the study, then monthly until month 24, then an additional visit at month 36

2017 Lancet Controlled trial quality: predicted high

15. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma:

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were compared (...) Oncology Group performance status score of 2 or less, who were ineligible for bone marrow transplantation, were randomly assigned (1:1) to receive six or eight 21-day cycles of VR-CAP (intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and bortezomib 1·3 mg/m2, plus oral prednisone 100 mg/m2) or R-CHOP (intravenous vincristine 1·4 mg/m2 [2 mg maximum], rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, and doxorubicin 50 mg/m2, plus oral prednisone 100 mg/m2

2019 EvidenceUpdates

16. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer (...) . Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study.In the multicentre, international, randomised, phase 3 LATITUDE trial, eligible patients were aged 18 years or older, had newly diagnosed, high-risk, metastatic castration-naive prostate

2018 EvidenceUpdates

17. Dexamethasone vs prednisone for asthma treatment in the inpatient population

Dexamethasone vs prednisone for asthma treatment in the inpatient population Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

18. Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone

Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone (DECOR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2017 Clinical Trials

19. Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone. (Full text)

Treatment of severe poison ivy: a randomized, controlled trial of long versus short course oral prednisone. Toxidendron (poison ivy, oak, and sumac) contact dermatitis is a common complaint in the outpatient primary care setting with little evidence-based guidance on best treatment duration.This randomized, controlled trial examined the efficacy and side effects of a 5-day regimen of 40 mg oral prednisone daily (short course) compared to the same 5-day regimen followed by a prednisone taper

2014 Journal of clinical medicine research Controlled trial quality: uncertain

20. Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial. (PubMed)

Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial. Dexamethasone has a longer half-life than prednisone and is well tolerated orally. We compare the time needed to return to normal activity and the frequency of relapse after acute exacerbation in adults receiving either 5 days of prednisone or 2 days of dexamethasone.We randomized adult emergency department patients (aged 18 to 45 years) with acute exacerbations of asthma (peak (...) expiratory flow rate less than 80% of ideal) to receive either 50 mg of daily oral prednisone for 5 days or 16 mg of daily oral dexamethasone for 2 days. Outcomes were assessed by telephone follow-up.Ninety-six prednisone and 104 dexamethasone subjects completed the study regimen and follow-up. More patients in the dexamethasone group reported a return to normal activities within 3 days compared with the prednisone group (90% versus 80%; difference 10%; 95% confidence interval 0% to 20%; P=.049). Relapse

2011 Annals of Emergency Medicine Controlled trial quality: predicted high